Fig. 3From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trialKaplan–Meier plots for PFS per RECIST v1.1 and OS (N = 62). a PFS by IRC review; b PFS by investigator review; c OS. PFS = progression-free survival, OS = overall survival, IRC = independent review committee, CI = confidence interval, NE = not estimableBack to article page